Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial

Friedrich K Pühringer, Christopher Rex, Andreas W Sielenkämper, Casper Claudius, Per Bo Larsen, Martine E Prins, Matthias Eikermann, Karin S Khuenl-Brady

202 Citationer (Scopus)

Abstract

Sugammadex (Org 25969), a novel, selective relaxant binding agent, was specifically designed to rapidly reverse rocuronium-induced neuromuscular blockade. The efficacy and safety of sugammadex for the reversal of profound, high-dose rocuronium-induced neuromuscular blockade was evaluated.
OriginalsprogEngelsk
TidsskriftAnesthesiology News
Vol/bind109
Udgave nummer2
Sider (fra-til)188-97
Antal sider10
ISSN0747-4679
DOI
StatusUdgivet - 1 aug. 2008

Fingeraftryk

Dyk ned i forskningsemnerne om 'Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater